SRTD biotech secures seed financing: Side-effect free
RNA therapeutics active only in diseased cells

November 14, 2024

Jülich, Germany, 14 November 2024 – Jülich-based biotech start-up SRTD biotech GmbH has successfully closed a seven-figure seed financing round. The company will use the fresh capital to accelerate the development of novel RNA therapeutics. Based on a proprietary platform technology, SRTD biotech aims to develop highly efficient RNA-based drugs that are active only in diseased cells. The round was led by High-Tech Gründerfonds (HTGF), alongside renowned business angels who have backed the technology from its inception.

If we can make RNA-based therapeutics effective only in diseased cells, we will be able to take the fear out of many diseases such as cancer. We are working to achieve this goal in the near future.

Dr. Bernd Hoffmann, CEO of SRTD biotech

Side effects are usually the critical factor that limits the effectiveness of drugs against cancer or viral diseases. SRTD biotech is the first company to develop RNA-based therapeutics that are active only in diseased cells. This significantly increases both the efficacy of the treatment and its tolerability. The company is using the novel approach of ‘selectively expressed RNAs’, or seRNAs, as a first step in the development of a therapy for liver cancer and is exploiting the possibilities of its modular platform technology for further development in the field of cancer therapeutics and beyond.

As a platform technology, seRNAs are not limited to oncology, but offer a wide range of possibilities in other therapeutic areas such as autoimmune diseases. We will collaborate with pharmaceutical and biotech companies to further establish seRNAs as a new therapeutic modality and position SRTD as a preferred partner in this market in the future.

Dr Georg Lautscham, CFO, BD of SRTD biotech

With the closing of the seed financing round, SRTD biotech is able to confirm the robustness of the platform and to attract further partners. The aim is to bring drug candidates for liver cancer into clinical development within the next three years and to make the platform available for other applications.

Drug development is at a pivotal moment : genetic technologies can intervene in the disease process in a precise and highly efficient way and promise to enable therapies without side effects. We are delighted to support SRTD biotech in its efforts to become a leader in the rapidly evolving field of RNA-based therapeutics. As a seed investor, it is in our nature to support the development of early and disruptive technologies.

Dr Angelika Vlachou, Partner at HTGF

About SRTD biotech
SRTD biotech was founded in Jülich by Dr Bernd Hoffmann and Dr Heribert Bohlen. The aim of the biotech start-up is to develop highly efficient RNA-based drugs based on a proprietary platform technology. The team consists of experts in molecular biology, cell biology, chemistry, translational sciences and business development. For further information please visit: https://srtd-biotech.com/.

Contact
SRTD biotech GmbH
Bernd Hoffmann, CEO
b.hoffmann@srtd-biotech.com

About HTGF – High-Tech Gründerfonds 
HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing start-ups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports start-ups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Across its funds, HTGF has over 2 billion euros under management. Since its inception in 2005, HTGF has financed more than 770 start-ups and achieved over 180 successful exits.  
Fund investors in the public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital as well as 45 companies and family offices.  
For more information, please visit HTGF.de or follow us on LinkedIn.

Media contact
High-Tech Gründerfonds Management GmbH
Tobias Jacob, Senior Marketing & Communications Manager
T.: +49 228 – 82300 – 121
t.jacob@htgf.de